# INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma

> **NCT03692338** · NA · TERMINATED · sponsor: **Duke University** · enrollment: 2 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **BEHAVIORAL:** Exercise

## Key facts

- **NCT ID:** NCT03692338
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-19
- **Primary completion:** 2019-12-09
- **Final completion:** 2019-12-09
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2019-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03692338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03692338, "INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT03692338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*